StockMarketWire.com - Liberum Capital today reaffirms its buy investment rating on Shield Therapeutics Plc [LON:STX] and raised its price target to 116p (from 80p).

Story provided by StockMarketWire.com

Broker Forecasts data provided by www.sharesmagazine.co.uk